Tirzepatide and semaglutide are the two most prescribed GLP-1 medications in the world. Both work — but they work differently, cost differently, and suit different patients.
The short answer: tirzepatide tends to produce greater weight loss on average, but semaglutide has a longer track record, broader insurance coverage, and is often more accessible. Neither is universally "better" — the right choice depends on your health history, goals, and what your provider recommends.
This guide will help you have a more informed conversation with your prescriber.
Tirzepatide
Zepbound® / Mounjaro®
Compounded tirzepatide
Semaglutide
Wegovy® / Ozempic®
Compounded semaglutide
Full Comparison
Side-by-Side Breakdown
Based on published clinical trial data and FDA prescribing information as of 2026.
| Category | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Average Weight Loss | ~20–22% body weight (SURMOUNT trial) | ~15% body weight (STEP trial) |
| FDA Approval | Diabetes (Mounjaro) · Obesity (Zepbound) | Diabetes (Ozempic) · Obesity (Wegovy) · CV risk (Wegovy) |
| Dosing Frequency | Once weekly | Once weekly |
| Starting Dose | 2.5 mg | 0.25 mg |
| Maximum Dose | 15 mg | 2.4 mg (Wegovy) / 2.0 mg (Ozempic) |
| Brand-Name Cost | ~$1,060/month (Zepbound) | ~$935–1,349/month |
| Compounded Cost | ~$200–400/month | ~$150–350/month |
| Insurance Coverage | Growing — check your plan | More established coverage |
| Years on Market | Since 2022 | Since 2017 (Ozempic) |
| Cardiovascular Data | Emerging (SELECT-TIMI 65 ongoing) | Strong CV outcome data (SELECT trial) |
| Nausea / GI Side Effects | Comparable | Comparable |
| Injection Form | Auto-injector pen or compounded vial | Auto-injector pen or compounded vial |
✦ Recommended Providers
Find Your GLP-1 Provider
Compare the top telehealth platforms — all require a medical evaluation before prescribing.
Fast onboarding, no contract, injection or tablet options. LegitScript certified.
Get Started →Same-day physician consult, board-certified doctors, unlimited messaging.
Learn More →Lower-pressure onboarding. Great for patients exploring their options.
Explore →Money-back guarantee if you do not lose 10% body weight. All 50 states.
Learn More →* Affiliate links — we may earn a commission at no cost to you. All providers require a medical evaluation before prescribing.
Who Should Consider Which
Scenario-Based Guide
These are general considerations — always discuss with your prescribing provider.
You want maximum weight loss
Clinical trials show tirzepatide produces greater average weight loss — around 20–22% vs 15% for semaglutide. For patients whose primary goal is significant weight reduction, tirzepatide may be the stronger option.
Consider TirzepatideYou have type 2 diabetes
Both medications are effective for blood sugar control. Semaglutide (Ozempic) has a longer track record for diabetes management and stronger cardiovascular outcome data. Tirzepatide (Mounjaro) also has strong glycemic control data. Your provider will weigh your specific cardiac risk profile.
Discuss with your providerYou have cardiovascular disease
Semaglutide has the SELECT trial data showing significant reduction in major cardiovascular events in people with obesity and established cardiovascular disease. Tirzepatide's cardiovascular trial data is still emerging. For high cardiac risk patients, semaglutide currently has stronger evidence.
Lean toward SemaglutideCost is your primary concern
Compounded semaglutide is generally slightly less expensive than compounded tirzepatide. Semaglutide also has more established insurance coverage pathways. If cost is the deciding factor, semaglutide may be more accessible.
Lean toward SemaglutideYou've tried semaglutide and plateaued
Some patients who reach a weight loss plateau on semaglutide see additional results when switching to tirzepatide due to its dual mechanism. This is a clinical decision — discuss with your provider before switching.
Ask about TirzepatideYou're new to GLP-1 medications
Both are appropriate starting points. Semaglutide has more published long-term data. Tirzepatide has shown stronger weight loss results. Your provider will consider your full medical history, goals, and insurance situation.
Discuss with your providerReady to get started with GLP-1?
Compare the top telehealth platforms — pricing, clinical oversight, and what to look for before you choose.
See All Providers → Sprout — From $199/mo → bmiMD — Clinical Support →